Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population in Canada, the United States, and Europe. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAle… Read more
Market Cap & Net Worth: Nymox Pharmaceutical Corporation (NYMXF)
Nymox Pharmaceutical Corporation (PINK:NYMXF) has a market capitalization of $9.56 Million ($9.56 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #31059 globally and #10226 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nymox Pharmaceutical Corporation's stock price $0.10 by its total outstanding shares 93540096 (93.54 Million).
Nymox Pharmaceutical Corporation Market Cap History: 2015 to 2025
Nymox Pharmaceutical Corporation's market capitalization history from 2015 to 2025. Data shows change from $306.81 Million to $9.56 Million (-30.58% CAGR).
Nymox Pharmaceutical Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nymox Pharmaceutical Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-5986.57x
Nymox Pharmaceutical Corporation's market cap is -5986.57 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $205.79 Million | $116.00K | -$13.16 Million | 1774.04x | N/A |
| 2020 | $231.98 Million | $5.00K | -$11.74 Million | 46395.89x | N/A |
| 2021 | $121.60 Million | $-5.00K | -$12.54 Million | -24320.42x | N/A |
| 2022 | $29.93 Million | $-5.00K | -$6.58 Million | -5986.57x | N/A |
Competitor Companies of NYMXF by Market Capitalization
Companies near Nymox Pharmaceutical Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to Nymox Pharmaceutical Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nymox Pharmaceutical Corporation Historical Marketcap From 2015 to 2025
Between 2015 and today, Nymox Pharmaceutical Corporation's market cap moved from $306.81 Million to $ 9.56 Million, with a yearly change of -30.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.56 Million | +36.09% |
| 2024 | $7.02 Million | -87.27% |
| 2023 | $55.19 Million | +84.38% |
| 2022 | $29.93 Million | -75.38% |
| 2021 | $121.60 Million | -47.58% |
| 2020 | $231.98 Million | +12.73% |
| 2019 | $205.79 Million | +67.94% |
| 2018 | $122.54 Million | -60.30% |
| 2017 | $308.68 Million | +23.60% |
| 2016 | $249.75 Million | -18.60% |
| 2015 | $306.81 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Nymox Pharmaceutical Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.56 Million USD |
| MoneyControl | $9.56 Million USD |
| MarketWatch | $9.56 Million USD |
| marketcap.company | $9.56 Million USD |
| Reuters | $9.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.